IBS and gut microbes: what newer research means for treatment

November 7, 2026

Irritable bowel syndrome has no scan or blood test of its own. Doctors diagnose it from the pattern of symptoms using criteria set by the Rome Foundation, and the StatPearls reference chapter on IBS describes this as a positive diagnosis, made from what the symptoms look like rather than only after everything else has been ruled out. That still leaves many people with IBS wondering what is actually happening inside their gut.

The microbes that live in the gut have become one of the busiest areas of IBS research. Some of that work has changed how doctors think about particular groups of patients, especially people whose main problems are constipation or bloating. A good deal of it is still early, and some of the most heavily marketed ideas have not done well in trials. If you are new to IBS itself, our plain-language introduction to IBS covers the basics.

Gut microbes in IBS differ, but not in one consistent way

Many studies have compared gut bacteria in people with and without IBS, and on average the two groups are different. The trouble is that the differences don't repeat reliably from one study to the next. A 2025 review in Frontiers in Immunology concluded that researchers have not found a universal IBS microbiome signature. The authors put this down largely to differences in how samples were collected and analyzed, and to how varied people with IBS are. Most studies also couldn't tell the IBS subtypes apart by their microbes.

The review's overall reading is that disturbed gut microbes go along with IBS symptoms rather than acting as one uniform cause. The link with infection is more concrete. Some people develop IBS after a bout of gastroenteritis, and the review links this post-infectious form to long-lasting immune activity in the lining of the gut.

Methane, archaea and constipation

One line of research links a gas, methane, with constipation. Not every microbe in the gut is a bacterium. Archaea are single-celled organisms in a separate group of their own, and some of them produce methane. Part of that gas passes into the bloodstream and is breathed out, which is why it can be measured with a breath test.

In 2024, researchers at Cedars-Sinai pooled 19 studies that recorded symptoms in people with an excess of these methane producers, a condition called intestinal methanogen overgrowth (IMO). People with IMO were more likely to have constipation, particularly severe constipation, and less likely to have persistent diarrhea. The Frontiers review describes a similar pattern within IBS, where constipation-predominant IBS is often linked with more methane-producing organisms and slower movement through the gut.

These are associations. They don't show that methane causes IBS with constipation, and plenty of people with that diagnosis won't have raised methane. For those who do, it can change the conversation about treatment. The Cedars-Sinai team pointed out that laxatives may ease constipation without helping other symptoms, and can make coexisting bloating or diarrhea worse. Treatment for IMO typically combines antibiotics with a specialized diet, and our IMO explainer goes into how it is diagnosed and managed.

Where SIBO fits in

Small intestinal bacterial overgrowth, or SIBO, means an excess of bacteria in the small intestine. Its symptoms overlap a lot with IBS, especially bloating, gas and diarrhea. The North American consensus on hydrogen and methane breath testing suggests breath tests in the assessment of conditions with bloating, and its authors call them a useful tool for people with unexplained IBS-like symptoms.

The same consensus set out the cutoffs. A rise in hydrogen of at least 20 parts per million (ppm) above the starting level by 90 minutes suggests SIBO. It also counts a methane level of at least 10 ppm as positive, the finding now called IMO. Because the two gases point to different organisms, it is worth checking that a breath test measures both.

Breath tests are far from perfect. A 2024 review of SIBO in Current Infectious Disease Reports notes that their reported accuracy varies widely between studies and that up to 20% of healthy people can test positive. The same review describes sequencing studies in which people with SIBO tended to carry more bacteria from the Enterobacteriaceae family, which includes E. coli and Klebsiella, and in which higher levels went along with more bloating. That helps explain the condition, but diagnosis still rests on breath testing or, less often, a fluid sample taken during an endoscopy. Our SIBO explainer covers testing and treatment in more detail.

Treatments aimed at gut microbes

Rifaximin

The antibiotic rifaximin is an established option for IBS with diarrhea, and the Frontiers review lists it among the first-line treatments. It doesn't permanently reset anything. The changes it makes to gut bacteria fade, and the review notes that some people's symptoms return after about ten weeks on average, so repeat courses are sometimes needed.

Elemental diets

An elemental diet replaces all food, typically for two to three weeks, with a liquid formula of nutrients in a pre-digested, easily absorbed form. It is used for SIBO and IMO rather than for IBS in general. It is also hard to stick to, which is why researchers have been testing better-tasting versions.

Much of the recent attention on elemental diets comes from one small trial of a more palatable formula, registered as NCT05978973. Thirty adults with SIBO or IMO drank only the formula for two weeks, then went back to their usual food for two more. There was no comparison group. Early results were presented at a conference in 2024 and summarized in the Current Infectious Disease Reports review: breath tests returned to normal in all six participants who had SIBO alone and in nine of the twelve (75%) who had both SIBO and IMO. The full results were published in Clinical Gastroenterology and Hepatology in 2025. According to the Cedars-Sinai announcement, 83% of participants said they felt better at the end of the trial, methane levels had dropped, and most people tolerated the formula without serious side effects.

That is encouraging but thin. Without a comparison group, the trial can't separate the formula's effect from other reasons people improve. The subgroups were tiny, and follow-up ended two weeks after normal eating resumed, so it says nothing about how long the benefit lasts. Several of the authors reported ties to companies in the field, and the team plans larger studies to look at longer-term results.

Probiotics

The Frontiers review rates the overall certainty of evidence for probiotics in IBS as low to very low, notes that any effect depends on the specific strain, and reports that the American College of Gastroenterology advises against using them routinely for overall IBS symptoms. A few single strains have moderate-certainty support.

Fiber and other supplements

In a 2025 double-blind, placebo-controlled trial in the Journal of Nutritional Science, 70 adults with IBS took resistant starch, pea fiber, chondroitin sulfate, a protein hydrolysate or a placebo for four weeks. None of the supplements raised Bifidobacterium, the trial's main measure, compared with placebo, and changes in symptoms and quality of life were not significantly different from placebo.

Fecal microbiota transplantation

Fecal microbiota transplantation (FMT) transfers gut microbes from a healthy donor's stool. In IBS its trial results have been mixed. The Frontiers review cites a 2024 meta-analysis that found no significant short-term benefit over placebo, and those authors concluded that the evidence doesn't support using FMT for IBS in routine care.

The low-FODMAP diet

The low-FODMAP diet cuts back on a group of carbohydrates that gut bacteria ferment, and in the Frontiers review's assessment it has the strongest evidence of any diet for IBS. It also changes the microbiome. Across the studies the review looked at, it consistently lowered levels of Bifidobacterium without a consistent change in overall diversity. What that means over the long run isn't known.

Microbiome stool tests sold to consumers

Stool tests that promise a personalized readout of your gut bacteria are easy to order online. In late 2024 an international consensus statement on microbiome testing, published in Lancet Gastroenterology & Hepatology, concluded that there isn't enough evidence to recommend routine microbiome testing in clinical practice. The panel discouraged people from requesting these tests without a clinical recommendation and discouraged testing companies from including treatment advice in their reports. Any change in treatment, it said, should come from the doctor who referred you. Breath tests for SIBO and IMO are a different kind of test, with their own criteria.

What this means if you have IBS

The research hasn't replaced the usual approach to IBS. Diet changes, medicines matched to the main symptoms and gut-brain therapies are still the backbone of care.

What it has added is more specific. If constipation or bloating dominate and standard treatment hasn't helped, it is reasonable to ask a doctor whether a breath test that measures both hydrogen and methane makes sense, knowing that the test can give false positives. If diarrhea is the main problem, rifaximin is an established option, although symptoms can come back. And when a test, supplement plan or diet promises to fix your microbiome, it's fair to ask what trial showed that, how many people took part and how long they were followed. For most microbiome-based treatments in IBS, the studies are still small, short or inconclusive.

This article is for general education and is not medical advice, so please talk to a doctor or other qualified clinician about your own symptoms and treatment.